Genmab A/S (OTCMKTS:GNMSF) Sees Large Growth in Short Interest

Genmab A/S (OTCMKTS:GNMSF) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 89,880 shares, a growth of 47.6% from the January 15th total of 60,883 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 106 shares, the days-to-cover ratio is currently 847.9 days. Based on an average trading volume of 106 shares, the days-to-cover ratio is currently 847.9 days. Currently, 0.1% of the company’s shares are sold short.

Genmab A/S Stock Performance

OTCMKTS GNMSF remained flat at $300.00 during mid-day trading on Friday. Genmab A/S has a 12 month low of $170.00 and a 12 month high of $352.00. The business’s 50 day moving average price is $326.19 and its two-hundred day moving average price is $296.72.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.